Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03206931 |
Expanded Access Status :
No longer available
First Posted : July 2, 2017
Last Update Posted : September 16, 2021
|
Sponsor:
Bayer
Information provided by (Responsible Party):
Bayer
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Brief Summary:
Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.
Condition or disease | Intervention/treatment |
---|---|
Solid Tumors Harboring NTRK Fusion | Drug: Selitrectinib (BAY2731954) |
Study Type : | Expanded Access |
Expanded Access Type : | Individual Patients |
See clinical trials of the intervention/treatment in this expanded access record. | |
Official Title: | Expanded Access to Provide Selitrectinib (BAY2731954) for the Treatment of Cancers With a NTRK Gene Fusion. |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Genes and Gene Therapy
Intervention Details:
- Drug: Selitrectinib (BAY2731954)
Selitrectinib is administered as capsules or liquid formulation.Other Name: Loxo-195
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Month and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Criteria
Inclusion Criteria:
- Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion
- Previous treatment with a kinase inhibitor with known activity on TRK inhibition
- Unable to participate in an ongoing selitrectinib clinical trial
- Medically suitable for treatment with selitrectinib
Exclusion Criteria:
- Currently enrolled in an ongoing clinical study with a TRK inhibitor
No Contacts or Locations Provided
Responsible Party: | Bayer |
ClinicalTrials.gov Identifier: | NCT03206931 |
Other Study ID Numbers: |
21002 |
First Posted: | July 2, 2017 Key Record Dates |
Last Update Posted: | September 16, 2021 |
Last Verified: | September 2021 |
Keywords provided by Bayer:
Metastatic cancer Advanced cancer Neurotrophic tyrosine receptor kinase (NTRK) NTRK1 NTRK2 |
NTRK3 Fusion Positive Children Loxo-195 |
Additional relevant MeSH terms:
Selitrectinib Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |